Rezultati - Jin‐Ji Yang

Refine Results
  1. 1
    Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer

    Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer od Wen‐Zhao Zhong, Xue‐Ning Yang, Jianling Bai, Jin‐Ji Yang, Christian Manegold, Yi‐Long Wu

    Izdano 2008
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Multiple primary malignancies involving lung cancer

    Multiple primary malignancies involving lung cancer od Feng Li, Wen‐Zhao Zhong, Feiyu Niu, Ning Zhao, Jin‐Ji Yang, Hong‐Hong Yan, Yi‐Long Wu

    Izdano 2015
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Mutational landscape and characteristics of <scp>ERBB2</scp> in <scp>non‐small</scp> cell lung cancer

    Mutational landscape and characteristics of <scp>ERBB2</scp> in <scp>non‐small</scp> cell lung cancer od Xue‐Wu Wei, Xin Gao, Xu‐Chao Zhang, Jin‐Ji Yang, Zhihong Chen, Yi‐Long Wu, Qing Zhou

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Myocardial Extracellular Volume Fraction Measured by Cardiac Magnetic Resonance Imaging Negatively Correlates With Cardiomyocyte Breadth in a Healthy Porcine Model

    Myocardial Extracellular Volume Fraction Measured by Cardiac Magnetic Resonance Imaging Negatively Correlates With Cardiomyocyte Breadth in a Healthy Porcine Model od Zhang, Shi-Jun, Chang, Di, Jin, Ji-Yang, Wang, Ya-Ling, Wang, Lin, Wang, Yuan-Cheng, Wang, Zhen, Ju, Shenghong

    Izdano 2022
    Polni tekst Polni tekst Polni tekst
    Text
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance

    Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance od Zhen Wang, Jin‐Ji Yang, Jie Huang, Junyi Ye, Xu‐Chao Zhang, Hai‐Yan Tu, Han Han‐Zhang, Yi‐Long Wu

    Izdano 2017
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib

    Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib od Jin‐Hyoung Kang, Hua‐Jun Chen, Zheng Wang, Jing Liu, Bing Li, Tengfei Zhang, Zhenfan Yang, Yi‐Long Wu, Jin‐Ji Yang

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

    Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations od Yang-Si Li, Ben‐Yuan Jiang, Jin‐Ji Yang, Hai‐Yan Tu, Qing Zhou, Wei‐Bang Guo, Hong‐Hong Yan, Yi‐Long Wu

    Izdano 2016
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC

    Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC od Mei-Mei Zheng, Yang-Si Li, Hai‐Yan Tu, Ben‐Yuan Jiang, Jin‐Ji Yang, Qing Zhou, Chong‐Rui Xu, Xiaorong Yang, Yi‐Long Wu

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

    Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803) od Yi‐Long Wu, Caicun Zhou, Ying Cheng, Shun Lü, G.-Y. Chen, Cheng Huang, Yulu Huang, Hong‐Hong Yan, Shengxiang Ren, Yao-Bin Liu, Jin‐Ji Yang

    Izdano 2012
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification

    BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification od Ben‐Yuan Jiang, Xuchao Zhang, Jian Su, Wei Meng, Xue‐Ning Yang, Jin‐Ji Yang, Qing Zhou, Zhiyong Chen, Zhihong Chen, Zhi Xie, Shiliang Chen, Yi‐Long Wu

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    Intervertebral disc regeneration using platelet-rich plasma-containing bone marrow-derived mesenchymal stem cells: A preliminary investigation

    Intervertebral disc regeneration using platelet-rich plasma-containing bone marrow-derived mesenchymal stem cells: A preliminary investigation od WANG, SHAN-ZHENG, JIN, JI-YANG, GUO, YU-DONG, MA, LIANG-YU, CHANG, QING, PENG, XIN-GUI, GUO, FANG-FANG, ZHANG, HAI-XIANG, HU, XIN-FENG, WANG, CHEN

    Izdano 2016
    Polni tekst Polni tekst Polni tekst
    Text
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

    Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression od Xu‐Chao Zhang, Shirley Zhang, Xue‐Ning Yang, Jin‐Ji Yang, Qing Zhou, Lucy Yin, Shejuan An, Jia-Yin Lin, Shiliang Chen, Zhi Xie, Mike Zhu, Xiaolin Zhang, Yi‐Long Wu

    Izdano 2010
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

    Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients od Si‐Yang Maggie Liu, Hao Sun, Jiaying Zhou, Guang‐Ling Jie, Zhi Xie, Yang Shao, Xian Zhang, Junyi Ye, Chunxiang Chen, Xu‐Chao Zhang, Qing Zhou, Jin‐Ji Yang, Yi‐Long Wu

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

    Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial od Qing Zhou, Jin‐Ji Yang, Zhihong Chen, Xu‐Chao Zhang, Hong‐Hong Yan, Chong‐Rui Xu, Jian Su, Hua‐Jun Chen, Hai‐Yan Tu, Wen‐Zhao Zhong, Xue‐Ning Yang, Yi‐Long Wu

    Izdano 2016
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

    A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R od E‐E Ke, Qing Zhou, Qiuyi Zhang, Jian Su, Zhihong Chen, Xu‐Chao Zhang, Chong‐Rui Xu, Jin‐Ji Yang, Hai‐Yan Tu, Hong‐Hong Yan, Yichen Zhang, Feiyu Niu, Yi‐Long Wu

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Molecular characteristics and clinical outcomes of <i>EGFR</i> exon 19 indel subtypes to EGFR TKIs in NSCLC patients

    Molecular characteristics and clinical outcomes of <i>EGFR</i> exon 19 indel subtypes to EGFR TKIs in NSCLC patients od Jian Su, Wen‐Zhao Zhong, Xu‐Chao Zhang, Ying Huang, Hong‐Hong Yan, Jin‐Ji Yang, Zhong‐Yi Dong, Zhi Xie, Qing Zhou, Xiao-sui Huang, Danxia Lu, Wenqing Yan, Yi‐Long Wu

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

    Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status od Wen‐Zhao Zhong, Xue‐Ning Yang, Hong‐Hong Yan, Xu‐Chao Zhang, Jian Su, Zhihong Chen, Ri-Qiang Liao, Qiang Nie, Song Dong, Qing Zhou, Jin‐Ji Yang, Hai‐Yan Tu, Yi‐Long Wu

    Izdano 2015
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC

    The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC od Si‐Yang Maggie Liu, Lan-ying Gou, Anna Li, Na-Na Lou, Hongfei Gao, Jian Su, Jin‐Ji Yang, Xu‐Chao Zhang, Yang Shao, Zhong‐Yi Dong, Qing Zhou, Wen‐Zhao Zhong, Yi‐Long Wu

    Izdano 2016
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status

    Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status od She-Juan An, Zhi Hong Chen, Jian Su, Xu‐Chao Zhang, Wen-Zhao Zhong, Jin-Ji Yang, Qing Zhou, Xue-Ning Yang, Ling Huang, Ji-Lin Guan, Qiang Nie, Hong-Hong Yan, Tony Mok, Yi‐Long Wu

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

    Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclit... od Yi‐Long Wu, Nagahiro Saijo, Sumitra Thongprasert, James Chih‐Hsin Yang, Baohui Han, Benjamin Margono, B. Chewaskulyong, Patrapim Sunpaweravong, Yuichiro Ohe, Yukito Ichinose, Jin‐Ji Yang, Tony Mok, Helen Young, Vincent Haddad, Yuri Rukazenkov, Masahiro Fukuoka

    Izdano 2016
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: